Diagnostics News and Research RSS Feed - Diagnostics News and Research

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]
WellStar establishes new health park in East Cobb

WellStar establishes new health park in East Cobb

WellStar East Cobb Health Park opened its doors September 15, serving as a comprehensive, one-stop shop for outpatient medical needs. [More]
Danaher signs definitive transaction agreement with Nobel Biocare

Danaher signs definitive transaction agreement with Nobel Biocare

Danaher Corporation has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher Corporation or one of its direct or indirect subsidiaries ("Danaher") will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2 billion. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
Incidence of thyroid cancer rising faster in Pennsylvania than in rest of the United States as a whole

Incidence of thyroid cancer rising faster in Pennsylvania than in rest of the United States as a whole

Incidence of thyroid cancer is rising faster in Pennsylvania than in the rest of the United States as a whole, according to Penn State College of Medicine researchers. [More]
Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes. [More]
Gates Foundation pledges $50 million to support emergency efforts to control Ebola epidemic

Gates Foundation pledges $50 million to support emergency efforts to control Ebola epidemic

The Bill & Melinda Gates Foundation today announced that it will commit $50 million to support the scale up of emergency efforts to contain the Ebola outbreak in West Africa and interrupt transmission of the virus. [More]
BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences declares first sale of IOPtiMate system in Hong Kong

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate™ system in Hong Kong. [More]
USFDA clears Caya- contoured diaphragm for marketing in the United States

USFDA clears Caya- contoured diaphragm for marketing in the United States

The United States Food and Drug Administration (USFDA) has cleared the Caya- contoured diaphragm for marketing in the United States, bringing women one step closer to a new option for safe and effective non-hormonal contraception. [More]
Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers infuse antibody-studded iron nanoparticles into bloodstream to treat heart attack damage

Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage. [More]
Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Researchers identify non-protein-coding RNA whose expression linked to ovarian cancer

Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease. [More]
Study evaluates impact of myPath Melanoma diagnostic test

Study evaluates impact of myPath Melanoma diagnostic test

Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath- Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill. [More]
Novel virus could be source of severe respiratory disease in ball pythons

Novel virus could be source of severe respiratory disease in ball pythons

Researchers have identified a novel virus that could be the source of a severe, sometimes fatal respiratory disease that has been observed in captive ball pythons since the 1990s. The work is published this week in mBio-, the online open-access journal of the American Society for Microbiology. [More]
Researchers develop new methods that improve quality of myocardial perfusion imaging

Researchers develop new methods that improve quality of myocardial perfusion imaging

New methods that enhance the quality of myocardial perfusion imaging were developed in a recent study completed at the University of Eastern Finland. [More]
Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS). [More]
FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). [More]
Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes. [More]
Sepsis patients more likely to survive when treated at hospital with higher volume of cases

Sepsis patients more likely to survive when treated at hospital with higher volume of cases

Patients with sepsis, one of the most time-sensitive and hard-to-detect illnesses in medicine, are more likely to survive the life-threatening condition when treated at a hospital that sees a higher volume of sepsis cases. [More]